×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| Shyama Computronics and Servic | 0.70 | 0.19 | 0.61 | NA | 4.02 | 30.9 |
| Triochem Products Ltd., | 4.59 | 0.88 | NA | 3.60 | 0 | |
| Eris Lifesciences Limited | 7316.7 | 869.3 | 7274.5 | 6.14 | 17,413 | 52.9 |
| Concord Biotech Limited | 2589.5 | 759.21 | 2442.2 | 7.26 | 17264 | 52.9 |
| ASTRAZENECA PHARMA INDIA LTD. | 4482.71 | 308.51 | 4402.89 | 12.34 | 17176 | 102.0 |
Eris Lifesciences Limited, with Security Code 540596, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 328.7 | 355.3 | 332.0 | 314.5 | 411.2 | 409.7 | 324.4 | 341.2 | 456.6 | 428.7 |
| Expenses | 202.6 | 214.3 | 205.6 | 203.1 | 255.8 | 265.2 | 250.0 | 261.9 | 333.3 | 293.9 |
| Operating Profit | 126.2 | 141.0 | 126.4 | 111.5 | 155.5 | 144.5 | 74.4 | 79.4 | 123.4 | 134.8 |
| OPM % | 38.38% | 39.69% | 38.07% | 35.44% | 37.81% | 35.27% | 22.94% | 23.26% | 27.02% | 31.44% |
| Other Income | 3.4 | 6.2 | 3.5 | 4.3 | 4.0 | 7.0 | 3.4 | 20.4 | 5.2 | 13.6 |
| Interest | 7.2 | 7.5 | 3.1 | 3.0 | 6.8 | 6.5 | 15.1 | 28.9 | 56.2 | 56.3 |
| Depreciation | 15.0 | 15.9 | 16.5 | 17.3 | 20.2 | 25.0 | 28.1 | 29.1 | 45.6 | 46.2 |
| Profit before tax | 107.4 | 123.8 | 110.2 | 95.5 | 132.5 | 119.9 | 34.6 | 41.7 | 26.8 | 46.0 |
| Tax % | 11% | 7% | 9.8% | 8% | 16.4% | 1.8% | 8.6% | 5.4% | 36.5% | 38.9% |
| Net Profit | 95.6 | 115.2 | 99.4 | 87.8 | 110.7 | 117.8 | 31.7 | 39.5 | 17.0 | 28.1 |
| EPS in Rs | 7.03 | 8.46 | 7.31 | 6.43 | 8.13 | 8.65 | 2.33 | 2.9 | 1.25 | 2.06 |
| Metrics | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 460.5 | 423.3 | 402.8 | 466.6 | 505.3 | 486.3 | 550.9 | 719.7 | 739.0 | 727.5 |
| Expenses | 309.1 | 286.1 | 283.9 | 296.9 | 324.2 | 310.8 | 402.5 | 469.7 | 476.7 | 477.1 |
| Operating Profit | 151.5 | 137.2 | 118.9 | 169.7 | 181.1 | 175.5 | 148.4 | 250.0 | 262.3 | 250.3 |
| OPM % | 32.9% | 32.4% | 29.5% | 36.4% | 35.8% | 36.1% | 26.9% | 34.7% | 35.5% | 34.4% |
| Other Income | 5.2 | 2.2 | 1.0 | 1.0 | 3.5 | 4.2 | 15.1 | 1.6 | 6.8 | 4.2 |
| Interest | 7.1 | 3.0 | 8.9 | 17.4 | 16.3 | 18.1 | 33.0 | 60.4 | 59.5 | 57.2 |
| Depreciation | 28.6 | 29.9 | 35.1 | 40.9 | 42.1 | 45.7 | 53.9 | 75.9 | 80.5 | 81.2 |
| Profit before tax | 120.9 | 106.5 | 75.9 | 112.5 | 126.2 | 115.9 | 76.7 | 115.3 | 129.1 | 116.2 |
| Tax % | 1.3% | 5.9% | 19% | 16.7% | 3.1% | 12.4% | 3.9% | 22.5% | 25.4% | 25.2% |
| Net Profit | 119.4 | 100.2 | 61.5 | 93.6 | 122.3 | 101.5 | 79.6 | 89.4 | 96.4 | 86.9 |
| EPS in Rs | 8 | 7 | 4 | 6 | 9 | 7 | 5 | 6 | 6 | 6 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 11% |
| 3 Years: | 10% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 1% |
| 3 Years: | -5% |
| TTM: | -75% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 25% |
| 3 Years: | 24% |
| 1 Year: | 46% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 15% |
| 3 Years: | 18% |
| TTM: | 47% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 6% |
| 3 Years: | 3% |
| TTM: | -13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 25% |
| 3 Years: | 24% |
| 1 Year: | 46% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|